HomeComparePGLDF vs PFE

PGLDF vs PFE: Dividend Comparison 2026

PGLDF yields 413.22% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PGLDF wins by $14527.70M in total portfolio value
10 years
PGLDF
PGLDF
● Live price
413.22%
Share price
$0.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14527.75M
Annual income
$9,842,308,903.33
Full PGLDF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PGLDF vs PFE

📍 PGLDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPGLDFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PGLDF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PGLDF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PGLDF
Annual income on $10K today (after 15% tax)
$35,123.97/yr
After 10yr DRIP, annual income (after tax)
$8,365,962,567.83/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PGLDF beats the other by $8,365,940,247.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PGLDF + PFE for your $10,000?

PGLDF: 50%PFE: 50%
100% PFE50/50100% PGLDF
Portfolio after 10yr
$7263.90M
Annual income
$4,921,167,581.03/yr
Blended yield
67.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PGLDF
No analyst data
Altman Z
-1.6
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PGLDF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPGLDFPFE
Forward yield413.22%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$14527.75M$49.6K
Annual income after 10y$9,842,308,903.33$26,258.71
Total dividends collected$14100.40M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PGLDF vs PFE ($10,000, DRIP)

YearPGLDF PortfolioPGLDF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$52,022$41,322.31$9,153$693.39+$42.9KPGLDF
2$256,569$200,904.90$8,593$849.25+$248.0KPGLDF
3$1,200,550$926,021.09$8,336$1,066.78+$1.19MPGLDF
4$5,334,200$4,049,612.19$8,437$1,384.80+$5.33MPGLDF
5$22,523,445$16,815,850.82$9,013$1,875.40+$22.51MPGLDF
6$90,459,198$66,359,112.11$10,306$2,680.72+$90.45MPGLDF
7$345,868,960$249,077,617.64$12,820$4,101.38+$345.86MPGLDF
8$1,260,120,306$890,040,518.86$17,673$6,826.70+$1260.10MPGLDF
9$4,378,913,401$3,030,584,673.43$27,543$12,591.86+$4378.89MPGLDF
10$14,527,746,242$9,842,308,903.33$49,560$26,258.71+$14527.70MPGLDF

PGLDF vs PFE: Complete Analysis 2026

PGLDFStock

P2 Gold Inc., a junior mining company, engages in the acquisition, exploration, and development of mineral properties in Canada and the United States. It primarily explores for gold, copper, silver, lead, and zinc deposits. The company holds an interest in the Gabbs project comprising 421 unpatented lode mining claims and one patented lode mining claim covering 3,300 hectares in Nevada; the Silver Reef project covering an area of approximately 23,000 hectares; and the BAM property, which includes ten mineral tenures that covers an area of approximately 8,100 hectares. It also holds an interest in the Lost Cabin property comprising 106 unpatented lode mining claims covering an area of approximately 2,190 acres, located in Lake County, Oregon. The company was formerly known as Central Timmins Exploration Corp. and changed its name to P2 Gold Inc. in August 2020. P2 Gold Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full PGLDF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PGLDF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PGLDF vs SCHDPGLDF vs JEPIPGLDF vs OPGLDF vs KOPGLDF vs MAINPGLDF vs JNJPGLDF vs MRKPGLDF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.